Positive News SentimentPositive NewsNYSE:MED Medifast (MED) Stock Price, News & Analysis $13.95 -0.06 (-0.43%) As of 05/20/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Medifast Stock (NYSE:MED) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Medifast alerts:Sign Up Key Stats Today's Range$13.89▼$14.3850-Day Range$11.93▼$14.5452-Week Range$11.57▼$26.53Volume161,257 shsAverage Volume296,618 shsMarket Capitalization$153.32 millionP/E Ratio77.50Dividend YieldN/APrice Target$16.50Consensus RatingHold Company OverviewMedifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.Read More… Medifast Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreMED MarketRank™: Medifast scored higher than 70% of companies evaluated by MarketBeat, and ranked 73rd out of 147 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingMedifast has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMedifast has received no research coverage in the past 90 days.Read more about Medifast's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth200.00% Earnings GrowthEarnings for Medifast are expected to grow by 200.00% in the coming year, from $0.51 to $1.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medifast is 77.50, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.92.Price to Earnings Ratio vs. SectorThe P/E ratio of Medifast is 77.50, which means that it is trading at a more expensive P/E ratio than the Consumer Staples sector average P/E ratio of about 16.61.Price to Book Value per Share RatioMedifast has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Medifast's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.91% of the float of Medifast has been sold short.Short Interest Ratio / Days to CoverMedifast has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Medifast has recently decreased by 4.17%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldMedifast does not currently pay a dividend.Dividend GrowthMedifast does not have a long track record of dividend growth.Dividend SustainabilityBased on EPS estimates, Medifast will have a dividend payout ratio of 431.37% in the coming year. This indicates that Medifast may not be able to sustain their current dividend.Read more about Medifast's dividend. Sustainability and ESG2.0 / 5Environmental Score-4.00 Percentage of Shares Shorted10.91% of the float of Medifast has been sold short.Short Interest Ratio / Days to CoverMedifast has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Medifast has recently decreased by 4.17%, indicating that investor sentiment is improving. News and Social Media3.2 / 5News Sentiment1.71 News SentimentMedifast has a news sentiment score of 1.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Consumer Staples companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Medifast this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for MED on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Medifast insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.90% of the stock of Medifast is held by insiders.Percentage Held by Institutions95.51% of the stock of Medifast is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Medifast's insider trading history. Receive MED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter. Email Address MED Stock News HeadlinesMED Q1 Earnings Call: Revenue Misses, Coach Productivity and GLP-1 Strategy in FocusMay 12, 2025 | finance.yahoo.comEarnings Release: Here's Why Analysts Cut Their Medifast, Inc. (NYSE:MED) Price Target To US$15.00May 2, 2025 | finance.yahoo.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.May 21, 2025 | Porter & Company (Ad)Medifast First Quarter 2025 Earnings: EPS Beats ExpectationsMay 1, 2025 | finance.yahoo.comMedifast’s Earnings Call: Mixed Sentiment Amid ChallengesApril 29, 2025 | tipranks.comMedifast, Inc. (NYSE:MED) Q1 2025 Earnings Call TranscriptApril 29, 2025 | msn.comQ1 2025 Medifast Inc Earnings CallApril 29, 2025 | finance.yahoo.comMedifast Q1 2025 slides: Adapting strategy for GLP-1 era amid revenue challengesApril 29, 2025 | investing.comSee More Headlines MED Stock Analysis - Frequently Asked Questions How have MED shares performed this year? Medifast's stock was trading at $17.62 at the beginning of 2025. Since then, MED shares have decreased by 20.8% and is now trading at $13.95. View the best growth stocks for 2025 here. How were Medifast's earnings last quarter? Medifast, Inc. (NYSE:MED) issued its quarterly earnings data on Monday, April, 28th. The specialty retailer reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.04. The specialty retailer earned $115.73 million during the quarter, compared to analysts' expectations of $114.85 million. Medifast had a trailing twelve-month return on equity of 10.64% and a net margin of 0.35%. Read the conference call transcript. Who are Medifast's major shareholders? Top institutional shareholders of Medifast include Charles Schwab Investment Management Inc. (2.42%), American Century Companies Inc. (2.05%), AQR Capital Management LLC (1.82%) and Federated Hermes Inc. (1.60%). Insiders that own company stock include Scott Schlackman, Andrea B Thomas, Jeffrey J Brown and Constance J Hallquist. View institutional ownership trends. How do I buy shares of Medifast? Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Medifast own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medifast investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and AUO (AUOTY). Company Calendar Last Earnings4/28/2025Today5/21/2025Next Earnings (Estimated)8/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorConsumer Staples Industry Miscellaneous food preparations & kindred products Sub-IndustryPersonal Products Current SymbolNYSE:MED CIK910329 Webwww.medifast1.com Phone(410) 581-8042Fax410-581-8070Employees870Year FoundedN/APrice Target and Rating Average Stock Price Target$16.50 High Stock Price Target$16.50 Low Stock Price Target$16.50 Potential Upside/Downside+18.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.65) Trailing P/E Ratio77.50 Forward P/E Ratio27.35 P/E GrowthN/ANet Income$99.42 million Net Margins0.35% Pretax Margin0.63% Return on Equity10.64% Return on Assets7.57% Debt Debt-to-Equity RatioN/A Current Ratio3.34 Quick Ratio2.55 Sales & Book Value Annual Sales$543.45 million Price / Sales0.28 Cash Flow$2.86 per share Price / Cash Flow4.88 Book Value$19.21 per share Price / Book0.73Miscellaneous Outstanding Shares10,991,000Free Float10,665,000Market Cap$153.32 million OptionableOptionable Beta0.96 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NYSE:MED) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medifast, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medifast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.